专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2022051286A1 N-LINKED GLYCOSYLATION INHIBITORS AND METHODS OF USING SAME 审中-公开
公开(公告)号：WO2022051286A1
公开(公告)日：2022-03-10
申请号：PCT/US2021/048474
申请日：2021-08-31
申请人： YALE UNIVERSITY
发明人： CONTESSA, Joseph, N. , VAN ZANDT, Michael
IPC分类号： A61K31/402 , A61K31/426 , A61K31/44 , C07D207/04 , C07D213/04 , C07D277/22
摘要： The present disclosure includes compounds, compositions, and methods for preventing or treating diseases associated with N-linked glycosylation and/or oligosaccharyltransferase function in a subject in need thereof. The methods comprise administering to the subject an effective amount of at least one compound and/or pharmaceutical composition of the disclosure.

2. 发明申请

WO2022046642A1 COMPOUNDS AND COMPOSITIONS FOR DISRUPTING PROGRAMMED RIBOSOMAL FRAMESHIFTING 审中-公开
公开(公告)号：WO2022046642A1
公开(公告)日：2022-03-03
申请号：PCT/US2021/047163
申请日：2021-08-23
申请人： YALE UNIVERSITY
发明人： GUO, Junjie , SUN, Yu
IPC分类号： C12N7/00 , G01N33/543 , G01N33/569
摘要： In one aspect, the present disclosure relates to a pyrrolidine substituted quinolone compound. In another aspect, the present disclosure relates to a method of treating, ameliorating, and/or preventing an RNA virus infection in a patient in need thereof, the method comprising administering to the patient a therapeutically effective amount of a pyrrolidine substituted quinolone compound to disrupt the programmed ribosomal frameshifting (PRF) of the RNA virus. In some embodiments, the RNA virus is SARS-CoV-2.

3. 发明申请

WO2021247367A1 COMPOUNDS AND COMPOSITIONS FOR TREATING, AMELIORATING, AND/OR PREVENTING SARS-COV-2 INFECTION AND/OR COMPLICATIONS THEREOF 审中-公开
公开(公告)号：WO2021247367A1
公开(公告)日：2021-12-09
申请号：PCT/US2021/034536
申请日：2021-05-27
申请人： YALE UNIVERSITY
发明人： WILEN, Craig
IPC分类号： A61K39/215 , A61P31/14 , C07K14/005
摘要： The present disclosure includes compositions and methods for treating, ameliorating, and/or preventing SARS-CoV-2 infection, and/or one or more complications thereof. In certain embodiments, the methods comprise administering a therapeutically effective amount of an inhibitor of a molecule in the SWI/SNF complex, inhibitor of a molecule in the TGFβ signaling pathway, and/or inhibitor of a histone regulator molecule to a subject in need thereof.

4. 发明申请

WO2011071912A1 LABEL-FREE CELLULAR MANIPULATION AND SORTING VIA BIOCOMPATIBLE FERROFLUIDS 审中-公开
标题翻译：通过生物化学反应器进行免疫细胞操纵和分选
公开(公告)号：WO2011071912A1
公开(公告)日：2011-06-16
申请号：PCT/US2010/059270
申请日：2010-12-07
申请人： YALE UNIVERSITY , KOSER, Hur
发明人： KOSER, Hur
IPC分类号： G01N33/49 , B03C1/32
CPC分类号： G01N15/1056 , B01L3/502715 , B01L3/50273 , B01L3/502761 , B01L2200/0636 , B01L2200/0652 , B01L2300/06 , B01L2300/0848 , B03C1/023 , B03C1/23 , B03C1/253 , B03C1/288 , B03C1/32 , B03C2201/18 , B03C2201/24 , B03C2201/26 , C12M47/04 , C12N13/00 , G01N2015/0065 , G01N2015/1006 , G01N2015/1081
摘要： A device for separating a sample of cells suspended in a bio-compatible ferrofluid is described The device includes a microfluidic channel having a sample inlet, at least one output, and a length between the sample inlet and the at least one output, wherein a sample can be added to the sample inlet and flow along the length to the at least one outlet The device includes a plurality of electrodes, and further includes a power source for applying a current to the plurality of electrodes to create a magnetic field pattern along the length of the microfluidic channel The present invention also includes a method of using said device for separating at least one cell type.
摘要翻译：描述了用于分离悬浮在生物相容性铁磁流体中的细胞样品的装置。该装置包括具有样品入口，至少一个输出和样品入口与至少一个输出之间的长度的微流体通道，其中样品可以被添加到样品入口并沿着长度流动到至少一个出口。装置包括多个电极，并且还包括用于向多个电极施加电流以产生沿着长度的磁场图案的电源的微流体通道本发明还包括使用所述装置分离至少一种细胞类型的方法。

5. 发明申请

WO2023278321A1 COMPOSITIONS AND METHODS FOR PERMEABILIZING THE BLOOD BRAIN BARRIER 审中-公开
公开(公告)号：WO2023278321A1
公开(公告)日：2023-01-05
申请号：PCT/US2022/035114
申请日：2022-06-27
申请人： YALE UNIVERSITY , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE)
发明人： EICHMANN, Anne , BOYÉ, Kevin , GERALDO, Luiz
IPC分类号： A61K39/395 , A61K47/42 , C07K16/18 , A61P25/00 , A61P25/28
摘要： The present disclosure relates to compositions and methods for use in generating temporary permeability of the blood brain barrier.

6. 发明申请

WO2022150584A1 NON-COVALENT INHIBITORS OF THE MAIN PROTEASE OF SARS-COV-2 AND METHODS OF USE 审中-公开
公开(公告)号：WO2022150584A1
公开(公告)日：2022-07-14
申请号：PCT/US2022/011608
申请日：2022-01-07
申请人： YALE UNIVERSITY
发明人： JORGENSEN, William L.
IPC分类号： A61K31/7125 , A61K38/08 , A61K39/39
摘要： Provided herein are compounds of formula (I) or (I-A), which act as non-covalent inhibitors of SARS-CoV2 main protease (Mpro). The compounds of formula (I) or (I-A) are useful in treating COVID-19 infections, as well as reducing or ameliorating symptoms associated with COVID-19 infection.

7. 发明申请

WO2015160412A2 NOVEL METHODS OF PREPARING NANODEVICES 审中-公开
标题翻译：制备纳米器件的新方法
公开(公告)号：WO2015160412A2
公开(公告)日：2015-10-22
申请号：PCT/US2015/012815
申请日：2015-01-26
申请人： THE REGENTS OF THE UNIVERSITY OF COLORADO , DRS RSTA, INC. (DRS TECHNOLOGIES)
发明人： BRIGHT, Victor M. , GEORGE, Steven , BROWN, Joseph J. , EIGENFELD, Nathan T. , GRAY, Jason M. , SKIDMORE, George Dee
IPC分类号： H01L23/28
CPC分类号： B82B3/008 , B05D3/145 , B05D7/24 , B81C1/0019 , B81C1/00492 , B82B1/005 , B82Y30/00 , C23C16/01 , C23C16/0245 , C23C16/14 , C23C16/403 , C23C16/45525 , C23C16/45553 , C23C16/45555 , C23C16/56 , H01L2924/0002 , H01L2924/00
摘要： The present invention relates to novel nano- and micro-electromechanical devices and novel methods of preparing them. In one aspect, the invention includes methods of preparing a nanodevice. In certain embodiments, the methods comprise coating a polymer layer with a first at least one thin solid material layer using atomic layer deposition (ALD), thus forming an ALD-generated layer. In other embodiments, the methods comprise patterning the first at least one thin solid material layer to form a nanodevice. In yet other embodiments, the methods comprise releasing the nanodevice from the polymer layer.
摘要翻译：本发明涉及新颖的纳米和微机电器件及其制备方法。一方面，本发明包括制备纳米器件的方法。在某些实施方案中，所述方法包括使用原子层沉积（ALD）涂覆具有第一至少一个薄固体材料层的聚合物层，从而形成ALD生成层。在其他实施例中，方法包括图案化第一至少一个细固体材料层以形成纳米器件。在其它实施方案中，所述方法包括从聚合物层释放纳米器件。

8. 发明申请

WO2015116178A1 FUSION PROTEINS FOR MODULATING REGULATORY AND EFFECTOR T CELLS 审中-公开
标题翻译：用于调节调节剂和效应物T细胞的融合蛋白
公开(公告)号：WO2015116178A1
公开(公告)日：2015-08-06
申请号：PCT/US2014/014197
申请日：2014-01-31
申请人： THOMAS JEFFERSON UNIVERSITY , THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
发明人： TYKOCINSKI, Mark, L.
IPC分类号： C07K14/525
CPC分类号： C07K14/70575 , C07K16/2878 , C07K2317/75 , C07K2319/00
摘要： The present invention provides fusion proteins that act on the glucocorticoid-induced TNFR family-related gene and OX40 signaling pathway. The proteins of the invention are useful in modulating both regulatory T cells and effector T cells. Compelling evidence from model systems points to immune surveillance mechanisms that can recognize and eliminate tumor cells. Yet established cancers commonly resist immune eradication, attributable in part to immunosuppressive elements within tumor microenvironments that limit the anti-tumor activity of infiltrating CD8+ cytotoxic T lymphocytes and other immune effectors. A variety of immunosuppressive mechanisms have been suggested to date, including tumor-intrinsic events, soluble suppressive factors, and regulatory cells capable of actively inhibiting effector T cell responses.
摘要翻译：本发明提供了作用于糖皮质激素诱导的TNFR家族相关基因和OX40信号通路的融合蛋白。本发明的蛋白质可用于调节调节性T细胞和效应T细胞。来自模型系统的令人信服的证据表明可以识别和消除肿瘤细胞的免疫监测机制。然而，已建立的癌症通常抵抗免疫根除，部分归因于肿瘤微环境内的免疫抑制因子，其限制了渗透性CD8 +细胞毒性T淋巴细胞和其他免疫效应物的抗肿瘤活性。目前已经提出了各种免疫抑制机制，包括肿瘤内在事件，可溶性抑制因子和能够主动抑制效应T细胞应答的调节细胞。

9. 发明申请

WO2022178263A1 MULTIVALENT NANO-'SELF' PEPTIDES AND USES THEREOF 审中-公开
公开(公告)号：WO2022178263A1
公开(公告)日：2022-08-25
申请号：PCT/US2022/017000
申请日：2022-02-18
申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
发明人： DISCHER, Dennis , JALIL, Abdelaziz
IPC分类号： A61K38/10 , A61K38/17 , C07K14/705
摘要： The present disclosure includes methods and compositions that can efficiently enhance macrophage-mediated phagocytosis of target cells by inhibiting the SIRPα/CD47 interaction in a way that minimizes off-target toxicity.

10. 发明申请

WO2020123674A1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME 审中-公开
公开(公告)号：WO2020123674A1
公开(公告)日：2020-06-18
申请号：PCT/US2019/065756
申请日：2019-12-11
申请人： ARBUTUS BIOPHARMA CORPORATION , ARBUTUS BIOPHARMA, INC.
发明人： COLE, Andrew G. , FAN, Yi , KULTGEN, Steven , MESAROS, Eugen
IPC分类号： A01N47/30 , C07C275/28 , A61P31/12
摘要： The present invention includes substituted arylmethyl ureas and heteroarylmethyl-ureas, and compositions comprising the same, that can be used to treat or prevent hepatitis B virus (HBV) infections in a patient.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式